Management of Myocardial Infarction in Children with Giant Coronary Artery Aneurysms after Kawasaki Disease

Acute myocardial infarction (AMI) is one of the most important causes of morbidity and mortality in Kawasaki disease, and patients with large or giant coronary aneurysms (z-score of ≥10 or absolute lumen diameter of ≥8 mm) are at greatest risk.1 For this reason, systemic anticoagulation together with antiplatelet therapy is recommended for all patients with Kawasaki disease with large/giant aneurysms.1 Even in the presence of therapeutic levels of anticoagulant medications and antiplatelet therapy, thrombosis in giant aneurysms can occur owing to unfavorable flow mechanics and decreased wall sheer stress in the aneurysm.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: Commentary Source Type: research